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as the number of symptomatic arterial disease locations
increases. A cost-utility analysis was undertaken comparing two
years of clopidogrel treatment with aspirin treatment for patients
with a previous history of MI, who then sustain an IS or a
peripheral arterial disease (PAD) event. These patients are
referred to as ‘high-risk’. METHODS: A model was constructed
to simulate hypothetical ‘high-risk’ patients. The time horizon
was that of patient lifetime with only direct medical costs con-
sidered. Health states included were vascular death, non-fatal IS
events and non-fatal MI events. The risk of future events in the
‘high-risk’ group compared with patients who had sustained a
single event (MI, IS or PAD) was calculated from the CAPRIE
trial and showed an 81% increase. This ratio was applied to
previously published risks of vascular death, non-fatal IS and
non-fatal MI for UK patients with a single event to calculate the
event rates for ‘high-risk’ patients. The relative risks (and 95%
conﬁdence intervals) of clopidogrel compared with aspirin in
‘high-risk’ patients in the CAPRIE trial were 0.87 (0.63–1.19),
0.83 (0.60–1.15) and 0.53 (0.32–0.86) for vascular death, non-
fatal IS and non-fatal MI events respectively. Costs and utilities
associated with events were taken from literature reviews and
were discounted at 3.5% per annum. Probabilistic sensitivity
analyses were undertaken. RESULTS: The mean cost per QALY
for clopidogrel compared with aspirin was 5443 (95% conﬁ-
dence interval 2332 to dominated). The probability of the cost
per QALY being below 20,000, a signiﬁcant threshold for
cost-effectiveness in the UK, was 79%. CONCLUSION: The
model suggests that, in patients with a previous MI event and
a subsequent IS or PAD event, clopidogrel can be considered
cost-effective compared with aspirin in terms of current UK
thresholds.
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OBJECTIVE: Proper diagnosis of Deep Vein Thrombosis (DVT)
at the earliest time is very important so that appropriate therapy
can be initiated. Various diagnostic tests have been developed for
DVT, but most of them have poor sensitivity and speciﬁcity. Due
to the above issues, it is very important that diagnosis strategies
be developed which are cost-effective. METHODS: Cost-
effectiveness was analyzed using a decision model from TreeAge
Pro Suite 2007 software. Outcomes considered were costs,
adverse events and quality adjusted life years (QALYs). Prob-
abilities were calculated using Bayes’ revision method that uti-
lized sensitivity and speciﬁcity of the diagnostic tests along with
the pretest probability of developing the disease. Quality of life
and costs data were pooled from literature reviews. QALYs were
calculated using life expectancy tables. Costs in pounds were
converted to US dollars and adjusted through use of Consumer
Price Index data from Bureau of Labor Statistics. RESULTS:
With a cost-effectiveness ratio of $32.4995 per QALY, the fol-
lowing strategy dominated other alternate strategies—Perform
venography if D-dimer test is positive. Otherwise, if D-dimer test
is negative then no treatment is given. If venography shows
abnormal results, treatment is given otherwise for normal results,
no treatment is given. Sensitivity analysis showed that this strat-
egy remained cost-effective even when all costs were varied by
25%. The model results were affected by the sensitivity of the
diagnostic tests. CONCLUSION: Based on this analysis, it would
be cost-effective if symptomatic patients are diagnosed with the
strategy after classifying them according to Wells score. Further
research needs to be done to see if cost of venography is offset by
decrease in hospitalization of those who later develop severe
form of DVT. Health care providers should consider patient
population distribution among the risk groups deﬁned by Wells
score before generalizing the ﬁnding.
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OBJECTIVE: This study was aimed to evaluate the economic
beneﬁts of clinical pharmacy service in hyperlipidaemic manage-
ment in accordance to the ATP III guidelines. METHODS: A
clinical pharmacy service was developed at the lipid clinic of
Prince of Wales Hospital (PWH) between October 2005 and
October 2007. In the intervention group, patients attended edu-
cational visits conducted by a clinical pharmacist. Medication
compliance and the proper use of drugs were assessed. Monthly
telephone follow-ups were made to check on the progress of
patients. The time spent by the pharmacist was recorded. In the
control group, patients received usual medical care with no phar-
macist intervention. RESULTS: A total of 300 patients were
recruited (150 in the intervention group and 150 in the control
group). Intervention group achieved 23.6%, 15.3%, and 22.3%
mean reduction in LDL-C, total cholesterol and triglyceride
levels, respectively, compared with 3.7%, 5.2%, and 2.7% in the
control group. A sustained reduction in total cholesterol of 1%
is associated with a 2–3% reduction in CHD risk. Pharmacist
conducted mean of 3.34 + 0.7 educational visits and 16.3 + 3.3
telephone follow-up calls. The overall time spent was 3.08
minutes per patient per week. The average monthly salary of a
hospital pharmacist was HK$30,000 (HK$7.8 = USD$1). In
previously published data, 0.39 patients per year at the PWH
lipid clinic experienced acute myocardial infarction (AMI) and
required HK$28,800 medical cost annually. Clinical pharmacy
service reduced the CHD risk of these patients and prevented the
development of an AMI, providing a potential cost saving of
HK$28,600 (which was 99% cost reduction) per patient per
year at PWH. (Estimated cost of pharmacist to manage 0.39
patients per year is HK$182.18). CONCLUSION: Clinical phar-
macy service is potentially a cost-effective way to improve the
management of hyperlipidaemia alongside with routine physi-
cian care.
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OBJECTIVE: To assess long-term reduction of cardiovascular
(CV) events and cost-effectiveness of the use of rosuvastatin
(RSV), atorvastatin (ATV), simvastatin (SIM) and pravastatin
(PRA) in Mexican patients over 55 years old. METHODS: Efﬁ-
cacy data from STELLAR clinical trial (total cholesterol -TC-,
LDL-C; HDL-C, triglycerides -TG-) was used as input to the
model. Based on Framingham risk equations, 4 gender/risk
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cohorts were traced for 20 years (4-year Markov cycles) with
55–76 year old patients in order to predict primary and second-
ary CV events. Quarterly titration in year one was set up to a
maximum dose of 20 mg RSV, 80 mg ATV, 80 mg SIM and
40 mg PRA based on TC target, whereas risk was calculated
using average TC : HDL-C ratio of the 1000 simulated patients,
with adjustment for Framingham’s hypothesized over-prediction
of Mexican risk. The economic analysis was done under private
sector perspective with a 5% and 1.5% discount rate for costs
and beneﬁts, respectively. Unitary costs were obtained from
NADRO (local wholesaler). Mexican Institute of Social Security
costs and data from a Delphi Panel were used to estimate
CV diseases’ private costs. Disability-adjusted life years gained
(DALYs) for each treatment regimen were estimated. Results are
shown in natural units, while costs are expressed in US dollars.
Sensitivity analysis included threshold, one-way scenarios and
probabilistic analysis. RESULTS: RSV 10 mg for the 20-year
horizon resulted in less primary and secondary events (197) and
deaths (42), per 1000 patients, more DALYs (14.97) and lower
per-patient treatment costs ($8134.57) than other statins on
equivalent doses. Hence, RSV 10 mg is highly cost-effective with
a cost per DALYs gained of $16,802.15 than comparators.
Sensitivity analysis showed the robustness of results. CONCLU-
SION: RSV is a cost-effective strategy: it yields fewer CV events,
resulting in fewer deaths and signiﬁcant economic saving for
both patients and institutions.
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OBJECTIVE: AVOID (Aliskiren in the Evaluation of Proteinuria
in Diabetes) was a multicentre, randomised, double-blind, six-
month study designed to assess the effect of adding aliskiren, an
oral direct renin inhibitor, to losartan and optimal antihyperten-
sive therapy (excluding ACE inhibitors), on the reduction in
urinary albumin to creatinine ratio (UACR) in patients with
hypertension, type 2 diabetes, and nephropathy. A cost-
effectiveness model was developed aiming to estimate the pro-
gression to end-stage renal disease (ESRD) and to project the
associated costs and clinical outcomes of aliskiren in the UK
setting. METHODS: A previously published Markov model of
diabetic nephropathy and ESRD was adapted to incorporate
treatment effects from AVOID, where aliskiren reduced mean
UACR versus placebo by 20% (p = 0.0009). Transition prob-
abilities from AVOID were used until patients reached UACR
>1,900 mg/g, with probabilities from the Irbesartan in Diabetic
Nephropathy Trial used thereafter. Direct medical costs were
based on UK pharmacy costs and published sources. Annual
discount rates of 3.5% were applied over the 20-year time
horizon. RESULTS: Short-term therapy beneﬁts associated with
aliskiren were projected to increase life expectancy by 0.0983
years (7.9175  0.0434 versus 7.8192  0.0369 years), improve
quality-adjusted life expectancy by 0.0878 quality-adjusted
life years (QALYs) (5.3038  0.0444 versus 5.2160  0.0391
QALYs) and reduce the cumulative incidence of ESRD by 2.51
percent (19.52% versus 22.03%) compared to placebo. An incre-
mental cost-effectiveness ratio of £12,073 per QALY gained was
calculated for aliskiren, which is well below the willingness-to-
pay threshold of the UK of £30,000 per QALY gained. Sensitivity
analysis where the clinical beneﬁt of aliskiren was extended
beyond UACR >1900 mg/g, proved to be a cost saving strategy.
CONCLUSION: Aliskiren would be considered cost-effective in
the UK setting when added to losartan therapy due to the addi-
tional renal protection provided and a reduced incidence of
ESRD.
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OBJECTIVE: To investigate the cost-effectiveness of a diagnostic
imaging strategy starting with magnetic resonance angiography
(MRA) enhanced with a blood pool agent versus strategies start-
ing with either MRA enhanced with conventional extracellular
agents or standard-DSA in severe peripheral arterial occlusive
disease (PAOD) in Canada. METHODS: A microsimulation
model focusing on “diagnostic conﬁdence” instead of “diagnos-
tic accuracy”, built by Kienbaum et al. (submitted for publica-
tion) for the European perspective was adapted to compare a
strategy with initial MRA with Gadofosveset to strategies with
either initial MRA with conventional extracellular contrast
media (standard-MRA) or a standard digital subtraction angiog-
raphy (standard-DSA) in the work-up of severe PAOD (critical
limb ischemia) in the Canadian setting. The model allows evalu-
ating aggregated mean costs per initial diagnostic modality as
well as incremental costs per quality-adjusted life year (QALY)
gained. Both efﬁcacy and utility data were derived from the
European analysis. Cost data were calculated from the payer
perspective and estimated by the ‘Program for the Assessment
of Technology in Health’ (PATH) at McMaster University.
RESULTS: The model simulation predicts an equivalent utility
score for all alternatives considered. From the payer perspective,
the mean overall cost of the Gadofosveset-MRA strategy amount
to $7814. In contrast, aggregated costs with either standard-
MRA or -DSA reach $8637 and $9842, respectively. Thus, an
imaging strategy with initial Gadofosveset-MRA is less costly
than strategies initially using standard-MRA or -DSA. With
regard to cost-effectiveness the additional costs per QALY gained
by standard-MRA versus Gadofosveset-MRA amount to about
$117,000 and about $178,000 for standard-DSA. The model
was robust regarding probabilistic variations of all parameters.
CONCLUSION: From the payer perspective in Canada, an
imaging strategy starting with Gadofosveset-MRA represents a
cost-effective option for the diagnostic work-up of severe PAOD
(critical limb ischemia) compared to strategies with either
standard-MRA or -DSA.
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OBJECTIVE: Some new antidiabetic drugs such as insulin
glargine, insulin detemir, exenatide, and rosiglitazone have been
widely used in the clinical practice. Very few pharmacoeconomics
studies on diabetes medications are focused on these drugs. To
compare and contrast the cost-effectiveness of the various diabe-
tes medications, we conducted the systematic review of drug-
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